NCT00543582 2015-07-01MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin LymphomaMirati Therapeutics Inc.Phase 2 Terminated23 enrolled